↓ Skip to main content

Complementary and synergistic therapeutic effects of compounds found in Kampo medicine: analysis of daikenchuto

Overview of attention for article published in Frontiers in Pharmacology, August 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 X users

Citations

dimensions_citation
68 Dimensions

Readers on

mendeley
53 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Complementary and synergistic therapeutic effects of compounds found in Kampo medicine: analysis of daikenchuto
Published in
Frontiers in Pharmacology, August 2015
DOI 10.3389/fphar.2015.00159
Pubmed ID
Authors

Toru Kono, Mitsuo Shimada, Masahiro Yamamoto, Atushi Kaneko, Yuji Oomiya, Kunitsugu Kubota, Yoshio Kase, Keiko Lee, Yasuhito Uezono

Abstract

Herbal medicines have been used in Japan for more than 1500 years and traditional Japanese medicines (Kampo medicines) are now fully integrated into the modern healthcare system. In total, 148 Kampo formulae are officially approved as prescription drugs and covered by the national health insurance system in Japan. However, despite their long track record of clinical use, the multi-targeted, multi-component properties of Kampo medicines, which are fundamentally different from Western medicines, have made it difficult to create a suitable framework for conducting well-designed, large-scale clinical trials. In turn, this has led to misconceptions among western trained physicians concerning the paucity of scientific evidence for the beneficial effects of Kampo medicines. Fortunately, there has been a recent surge in scientifically robust data from basic and clinical studies for some of the Kampo medicines, e.g., daikenchuto (TU-100). Numerous basic and clinical studies on TU-100, including placebo-controlled double-blind studies for various gastrointestinal disorders, and absorption, distribution, metabolism and excretion (ADME) studies, have been conducted or are in the process of being conducted in both Japan and the USA. Clinical studies suggest that TU-100 is beneficial for postoperative complications, especially ileus and abdominal bloating. ADME and basic studies indicate that the effect of TU-100 is a composite of numerous actions mediated by multiple compounds supplied via multiple routes. In addition to known mechanisms of action via enteric/sensory nerve stimulation, novel mechanisms via the TRPA1 channel and two pore domain potassium channels have recently been elucidated. TU-100 compounds target these channels with and without absorption, both before and after metabolic activation by enteric flora, with different timings and possibly with synergism.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
United States 1 2%
Unknown 51 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 12 23%
Student > Bachelor 8 15%
Student > Ph. D. Student 4 8%
Professor > Associate Professor 3 6%
Student > Master 3 6%
Other 8 15%
Unknown 15 28%
Readers by discipline Count As %
Agricultural and Biological Sciences 11 21%
Medicine and Dentistry 7 13%
Pharmacology, Toxicology and Pharmaceutical Science 4 8%
Nursing and Health Professions 2 4%
Biochemistry, Genetics and Molecular Biology 2 4%
Other 8 15%
Unknown 19 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 October 2022.
All research outputs
#19,629,732
of 24,995,611 outputs
Outputs from Frontiers in Pharmacology
#8,240
of 19,153 outputs
Outputs of similar age
#183,907
of 269,784 outputs
Outputs of similar age from Frontiers in Pharmacology
#33
of 69 outputs
Altmetric has tracked 24,995,611 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 19,153 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one is in the 49th percentile – i.e., 49% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 269,784 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 69 others from the same source and published within six weeks on either side of this one. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.